Retrospective evaluation of the patients with mantle cell lymphoma treated and followed in Gazi University Hospital

Objective: Mantle cell lymphoma which accounts for about 5% of all non-Hodgkin?s lymphomas is an agressive and noncurable disease. Since there is no accepted standart treatment protocol for the first line chemotherapy, we consider that every center has a treatment practice according to their own technical supplies, hospital bed and professional numbers. This study was planned to analyse the types, efficiacy and toxicity of the chemotherapy regimens preferred in Gazi University Hospital.Material and Method: The patients diagnosed with mantle cell lymphoma between January 2000 and December 2011 were analysed retrospectively. Forty-four patients were determined but medical records of four patients were not met. Thereby the demographic data,chmeotherapy regimens, treatment responses and toxicities of 40 patients were evaluated.Results: There were 33 male and 7 female patients in this study with a follow-up of median 33.5 (3-134) months. Twenty-six (65%) patients were alive whereas 14 (35%) of them were dead. Median age was 61.5 years old and 85% of patients had advanced stage disease. Blastoid subtype was found in eight patients. As first-line treatment; R-CHOP, RHyperCVAD, R-CVP and R-CMF were preferred in 27, 9, 3 and 1 patient respectively.Autologous bone marrow transplantation was done in 11 patients with 4 of them in first-line treatment. Complete response, partial response, stable disease and progressive disease were obtained in 24, 8, 4 and 2 patients respectively. Median disease-free survival was 18 months and overall survival hasn?t been reached. However 5-year survival was 58%. Grade3-4 myelosuppression was observed in the 83% of patients who had R-HyperCVAD and 52% of patients who had R-CHOP as first-line therapy and toxic death was seen in 1 patient.Conclusion: Mantle cell lymphoma is a disease with poor prognosis due to temporary chemotherapy response and high recurrence rate. Our first-line chemoherapy responses and toxicities were found to be consistent with the previous reports. Taking into consideration that there is no chance of cure, chemotherapy decision should be done according to age, performance status and comorbidities of the patient.